A Phase 4 interventional study of Rapamune in Kidney Failure and Graft vs Host Disease, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 5 sites in India. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2007-12-28.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing sirolimus in Renal Insufficiency — none open to participants now, none under way, none of them phase 3. Sirolimus · Renal Insufficiency.
Among the 16 studies testing sirolimus in Renal Insufficiency, this one is the 5th largest by enrollment, is one of 2 that started in 2004, is one of 6 in phase 4, and was the 5th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →None of the 16 studies testing sirolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →
Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4 · Phase 4 6
First in 2000; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 63 across the 16 interventional studies. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 8 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
37 studies in Renal Insufficiency by Pfizer: 2 open now, 3 under way, none of them phase 3. Of 34 finished, 15 (44%) have results posted.
Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 8th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2004, is one of 8 in phase 4, and was the 3rd registered.
Pfizer’s Renal Insufficiency studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing sirolimus in Renal Insufficiency, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 37 in Renal Insufficiency:
This tab as a report to print or save as PDF → With an account.
To determine the safety of sirolimus tablets in renal allograft recipients in a postmarketing surveillance setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Safety evaluation
The record gives a start of Apr 2004, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus
Wyeth is now a wholly owned subsidiary of Pfizer →